← Therapy pipeline
Investigational · Obesity development

Safiglipron (KAI-7535 / HRS-7535)

HRS-7535 · KAI-7535 · safiglipron · Kailera / Hengrui

Daily oral small-molecule GLP-1 agonist; China Phase 3 topline with a separate global Phase 2 underway.

GLP-1
Other study areas
Type 2 diabetes
Selected program areas, not approvals. See the full profile for individual trials.
Obesity stagePhase 3Updated as of November 2026
SponsorKailera / Hengrui
TargetsGLP-1
RouteOral tablet
DevelopmentObesity-specific
01 / Evidence

Selected study results

HARBOR-1 · China · primary analysisMean body-weight change from baselineBody weight decreased 9.79% · 44 weeks · Phase 3
Phase 3 · Oral · Sponsor conference poster

Mean body-weight change from baseline · 44 weeks

Study focus: Weight management

Primary treatment-policy analysis; global obesity development remains Phase 2.

Investigational regimen
9.79%
Placebo / comparator
2.39%

Adults with overweight or obesity in China, without diabetes · 180 mg once daily vs placebo · Trial N=556 · Primary treatment-policy estimand. Results & methods ↗

Additional results or analyses from this same study
  • Prespecified supplementary efficacy estimand · week 44The November poster reports 11.58% mean weight reduction with 180 mg versus 2.54% with placebo, assuming adherence.
  • Ad hoc efficacy analysis · week 50The November poster reports 11.92% versus 2.65% with placebo. This ad hoc model is separate from the prespecified week-44 supplementary analysis.
  • Earlier July 7 topline · historical estimatesThe July sponsor release reported 10.9% versus 2.5% for week-44 supplementary efficacy and 11.1% versus 2.6% for the ad hoc week-50 analysis. The November poster estimates above are a later reporting version; the primary week-44 treatment-policy result is unchanged. Follow-up source ↗

Gastrointestinal events were common at 180 mg: nausea 70.0%, vomiting 68.6%; 3.1% discontinued for adverse events. The supplementary and ad hoc analyses below are distinct from the primary endpoint.

Each graphic shows results within one study. Alternate analyses and follow-up from that study are labeled together. Study averages are not individual predictions or cross-trial comparisons.

Tolerability

Safety context

In HARBOR-1 at 180 mg once daily, nausea occurred in 70.0% and vomiting in 68.6%; 3.1% discontinued because of adverse events.

02 / How it works

Mechanism at a glance

GLP-1GLP-1Targeted
GIPGIP—
GCGglucagon—
AMYamylin—
OTHOther targets—
Explore the hormone anatomy ↗
03 / Development

Obesity stage by formulation

TabletOral tablet · Once daily
Phase 3China Phase 3 reported; global Phase 2 ongoing
Milestone → next

Latest: HARBOR-1 Phase 3 topline reported in China; global obesity Phase 2 began in April 2026.

Next: Global Phase 2 data are expected in 2027.

04 / Study records

Clinical study records

Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.

Obesity and weight-management studies

Phase 3 studies2 records

Phase 3

HARBOR-1 · China

Weight management
Study: CompletedResults: Sponsor conference results shown aboveStatus reviewed November 2026

556 adults with overweight or obesity in China, without diabetes; 120 or 180 mg once daily versus placebo. Primary treatment-policy endpoint at week 44; supplementary efficacy and ad hoc week-50 analyses are labeled separately.

Phase 3

OUTSTAND-2 · China T2D

Weight management with type 2 diabetes
Study: CompletedResults: No registry results posted yetStatus reviewed November 2026

Separate type 2 diabetes program; not the obesity development phase.

Phase 2 studies1 record

Phase 2

Global KAI-7535 obesity trial

Weight management
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

U.S. and Australia; initiated April 2026, with results expected in 2027.